Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L)

Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L)

Abstract Background The ALTA-1L study compared brigatinib with crizotinib in untreated ALK-rearranged non-small cell lung cancer (NSCLC) patients, demonstrating the efficacy of brigatinib. Although the median progression-free survival (PFS) of brigatinib group was 24.0 months, the one-year PFS rate...

Full description

Bibliographic Details
Main Authors: Kazushige Wakuda, Hirotsugu Kenmotsu, Yuki Sato, Atsushi Nakamura, Hiroaki Akamatsu, Motoko Tachihara, Satoru Miura, Toshihide Yokoyama, Keita Mori, Kazuhiko Nakagawa, Nobuyuki Yamamoto
Format: Article
Language:English
Published: BMC 2023-09-01
Series:BMC Cancer
Subjects:
Non-small cell lung cancer
ALK
Brigatinib
Pemetrexed
Chemotherapy
Online Access:https://doi.org/10.1186/s12885-023-11417-w

Internet

https://doi.org/10.1186/s12885-023-11417-w

Similar Items